390 related articles for article (PubMed ID: 30569186)
1. Response assessment using
Grubmüller B; Senn D; Kramer G; Baltzer P; D'Andrea D; Grubmüller KH; Mitterhauser M; Eidherr H; Haug AR; Wadsak W; Pfaff S; Shariat SF; Hacker M; Hartenbach M
Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1063-1072. PubMed ID: 30569186
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract][Full Text] [Related]
3. Change in total lesion PSMA (TLP) during [
Burgard C; Hein C; Blickle A; Bartholomä M; Maus S; Petto S; Schaefer-Schuler A; Ezziddin S; Rosar F
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):885-895. PubMed ID: 37889298
[TBL] [Abstract][Full Text] [Related]
4.
John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L
J Nucl Med; 2023 Mar; 64(3):410-415. PubMed ID: 36215568
[No Abstract] [Full Text] [Related]
5. Comparison of PET/CT-based eligibility according to VISION and TheraP trial criteria in end-stage prostate cancer patients undergoing radioligand therapy.
Michalski K; Kosmala A; Werner RA; Serfling SE; Seitz AK; Lapa C; Buck AK; Hartrampf PE
Ann Nucl Med; 2024 Feb; 38(2):87-95. PubMed ID: 37891376
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment
Eisazadeh R; Mirshahvalad SA; Schwieghofer-Zwink G; Hehenwarter L; Rendl G; Gampenrieder S; Greil R; Pirich C; Beheshti M
Mol Imaging Biol; 2024 Apr; 26(2):360-369. PubMed ID: 38360991
[TBL] [Abstract][Full Text] [Related]
7. PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [
Hotta M; Gafita A; Murthy V; Benz MR; Sonni I; Burger IA; Eiber M; Emmett L; Farolfi A; Fendler WP; Weber MM; Hofman MS; Hope TA; Kratochwil C; Czernin J; Calais J
J Nucl Med; 2023 Jul; 64(7):1024-1029. PubMed ID: 36997329
[TBL] [Abstract][Full Text] [Related]
8. Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [
Song H; Leonio MI; Ferri V; Duan H; Aparici CM; Davidzon G; Franc BL; Moradi F; Shah J; Bergstrom CP; Fan AC; Shah S; Khaki AR; Srinivas S; Iagaru A
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38635050
[TBL] [Abstract][Full Text] [Related]
9. Comparison of quantitative whole body PET parameters on [
Ayati N; McIntosh L; Buteau J; Alipour R; Pudis M; Daw N; Jackson P; Hofman MS
Cancer Imaging; 2024 May; 24(1):57. PubMed ID: 38711135
[TBL] [Abstract][Full Text] [Related]
10. Lesion Dosimetry for [
Grkovski M; O'Donoghue JA; Imber BS; Andl G; Tu C; Lafontaine D; Schwartz J; Thor M; Zelefsky MJ; Humm JL; Bodei L
J Nucl Med; 2023 Nov; 64(11):1779-1787. PubMed ID: 37652541
[TBL] [Abstract][Full Text] [Related]
11. Development of a Visually Calculated SUV
Swiha M; Papa N; Sabahi Z; Ayati N; John N; Pathmanandavel S; Crumbaker M; Li S; Agrawal S; Ayers M; Hickey A; Sharma S; Nguyen A; Emmett L
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637137
[No Abstract] [Full Text] [Related]
12. [
Schaefer-Schuler A; Burgard C; Blickle A; Maus S; Petrescu C; Petto S; Bartholomä M; Stemler T; Ezziddin S; Rosar F
Theranostics; 2024; 14(5):1829-1840. PubMed ID: 38505615
[No Abstract] [Full Text] [Related]
13. Comparison of novel PSMA-targeting [
Li L; Wang J; Wang G; Wang R; Jin W; Zang J; Sui H; Jia C; Jiang Y; Hong H; Zhu L; Alexoff D; Ploessl K; Kung HF; Zhu Z
Eur J Nucl Med Mol Imaging; 2024 Apr; ():. PubMed ID: 38658392
[TBL] [Abstract][Full Text] [Related]
14. Assessment of PSMA Expression of Healthy Organs in Different Stages of Prostate Cancer Using [
Einspieler H; Kluge K; Haberl D; Schatz K; Nics L; Schmitl S; Geist BK; Spielvogel CP; Grubmüller B; Baltzer PAT; Kramer G; Shariat SF; Hacker M; Rasul S
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672596
[TBL] [Abstract][Full Text] [Related]
15. Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to
Raychaudhuri R; Mo G; Tuchayi AM; Graham L; Gulati R; Pritchard CC; Haffner MC; Yezefski T; Hawley JE; Cheng HH; Yu EY; Grivas P; Montgomery RB; Nelson PS; Chen DL; Hope T; Iravani A; Schweizer MT
JCO Precis Oncol; 2024 Apr; 8():e2300634. PubMed ID: 38662984
[TBL] [Abstract][Full Text] [Related]
16. Renal outcomes of radioligand therapy: experience of
Gallyamov M; Meyrick D; Barley J; Lenzo N
Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
[TBL] [Abstract][Full Text] [Related]
17. The Impact of Baseline PSMA PET/CT Versus CT on Outcomes of
Bosch D; van der Velden KJM; Oving IM; Wyndaele DNJ; Weijs LE; van Schelven WD; Oyen WJG; Te Beek ET; van de Luijtgaarden ACM; Somford DM; Nagarajah J; Hermsen R; Mehra N; Gerritsen WR; van der Doelen MJ; van Oort IM
J Nucl Med; 2024 Apr; 65(4):541-547. PubMed ID: 38423781
[TBL] [Abstract][Full Text] [Related]
18. Neuron-specific enolase has potential value as a biomarker for [
Rosar F; Ribbat K; Ries M; Linxweiler J; Bartholomä M; Maus S; Schreckenberger M; Ezziddin S; Khreish F
EJNMMI Res; 2020 May; 10(1):52. PubMed ID: 32449086
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Nephrotoxicity of
Steinhelfer L; Lunger L; Cala L; Pfob CH; Lapa C; Hartrampf PE; Buck AK; Schäfer H; Schmaderer C; Tauber R; Brosch-Lenz J; Haller B; Meissner VH; Knorr K; Weber WA; Eiber M
J Nucl Med; 2024 Jan; 65(1):79-84. PubMed ID: 37857504
[TBL] [Abstract][Full Text] [Related]
20. RECIP 1.0 Predicts Progression-Free Survival After [
Gafita A; Djaileb L; Rauscher I; Fendler WP; Hadaschik B; Rowe SP; Herrmann K; Solnes LB; Calais J; Rettig MB; Weber M; Farolfi A; Benz MR; Eiber M
J Nucl Med; 2024 Apr; ():. PubMed ID: 38637143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
